American Healthcare REIT, Inc. (AHR) Stock Analysis and Metrics

American Healthcare REIT

NYSE: AHR

$57.46 ▲ +1.08 (+1.92%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap10.71 Bn

P/E194.58

P/S4.76

Div. Yield0.00

ROIC (Qtr)-0.02

Total Debt (Qtr)1.51 Bn

Revenue Growth (1y) (Qtr)22.65

Add ratio to table…

About

American Healthcare REIT, Inc. is a self-managed real estate investment trust that acquires, owns and operates a diversified portfolio of clinical healthcare real estate properties throughout the United States, and in the United Kingdom and the Isle of Man. The company focuses primarily on senior housing, skilled nursing facilities, outpatient medical buildings, and other healthcare-related facilities. It operates an integrated management platform with approximately 121 employees as of December 31, 2025.

American Healthcare REIT, Inc. generates revenue primarily through leasing its real estate properties to third-party tenants and operators. Revenue streams include rental income from triple-net leased properties, operating income from properties managed under a RIDEA structure via its taxable REIT subsidiaries, and interest income from real estate-related investments such as mortgage loans. The company serves a broad base of healthcare providers, including hospitals, physician practices, senior housing operators, and skilled nursing facility operators.

The company operates through the following segments: Integrated Senior Health Campuses (ISHC), Outpatient Medical (OM), Senior Housing Operating Properties (SHOP), and triple-net leased properties.

• Integrated Senior Health Campuses: This segment provides a continuum of care for residents requiring increasing levels of care, including independent living, assisted living, memory care, skilled nursing, and certain ancillary services within a single campus setting. As of December 31, 2025, the company owned and/or operated 147 ISHC properties. Predominantly all of these facilities are operated utilizing a RIDEA structure, allowing the company to participate in operational upside while bearing the risk of performance declines.

• Outpatient Medical: This segment includes 74 outpatient medical buildings leased to third parties as of December 31, 2025. These properties are similar to commercial office buildings but require specialized infrastructure to accommodate physicians’ offices, examination rooms, pharmacies, hospital ancillary service space, and outpatient services such as diagnostic centers, rehabilitation clinics, and outpatient surgery operating rooms. The buildings are typically multi-tenant properties leased to healthcare providers under leases that provide for recovery of certain operating expenses and capital expenditures, with initial terms of five to 15 years and fixed annual rent escalations historically ranging from 2% to 3% per year.

• Senior Housing Operating Properties: As of December 31, 2025, the company owned and operated 97 senior housing and skilled nursing facilities in this segment. These facilities cater to different segments of the elderly population and include independent living, assisted living, memory care, and skilled nursing services. Services are primarily paid for by residents directly or through private insurance, making them less reliant on government reimbursement programs such as Medicaid and Medicare. The SHOP segment is operated utilizing RIDEA structures, allowing participation in operational upside while bearing performance risk.

• Triple-Net Leased Properties: This segment includes senior housing, skilled nursing facilities, and hospitals leased to tenants under triple-net or absolute-net leases. As of December 31, 2025, the company owned six skilled nursing facilities, 11 senior housing facilities, one wholly-owned hospital, and one hospital in which it holds an approximately 90.6% interest within this segment. Tenants in these properties are obligated to pay all property-related expenses, including maintenance, utilities, repairs, taxes, insurance, and capital expenditures. Leases typically have initial terms ranging from 14 to 29 years with fixed annual rent escalations historically ranging from 2% to 3% per year and require minimum lease coverage ratios.

American Healthcare REIT, Inc. operates in a competitive landscape with other real estate investment trusts and private investors focused on healthcare real estate. The company differentiates itself through its focus on quality, location, strong local health systems and operating partners, predictable capital needs, and cash flow generation. Its ability to invest across the healthcare real estate spectrum and utilize the RIDEA structure provides flexibility in capturing operational improvements while managing risk.

The company’s customer base includes healthcare providers such as hospitals, physician practices, senior housing operators, and skilled nursing facility operators. Specific tenant names are not disclosed in the filing, but the company leases properties to single tenants or operators under long-term agreements, particularly in its triple-net leased properties segment, and relies on third-party operators to manage its RIDEA-structured properties.

Investment Thesis

▲ Bull case

American Healthcare REIT (AHR) is positioned to capture significant value from its strategic focus on high-growth SHOP assets, which delivered 19.7% same-store NOI growth in Q1 2026 and expanded NOI margins by 215 basis points to 20.6%, driven by superior operator execution and dynamic revenue management. The company has successfully executed on its acquisition strategy, closing $249.2 million in SHOP deals year-to-date, including $162.8 million in Q1 and $86.4 million post-quarter in Georgia and South Carolina, with a robust pipeline of over $650 million in awarded deals—80% involving existing operators where AHR holds informational advantages through deep relationships and operator-first underwriting. This enables AHR to acquire assets below replacement cost in supply-constrained markets, leveraging certificate-of-need (CON) regimes as a durable competitive moat that limits new skilled nursing supply, particularly in key states like Wisconsin where Trilogy is pursuing regional scale. The development pipeline, totaling $173.9 million in-process with $52.4 million funded, is heavily weighted toward Trilogy campus expansions and independent living villas—asset types with higher margins—and extends AHR’s earnings runway through integrated senior health campuses that benefit from operational synergies across independent living, assisted living, and skilled nursing under one roof. Management’s statement that “We are still buying below replacement cost” underscores a persistent valuation advantage, especially as construction costs rise and new supply remains constrained by CON laws and unfavorable development economics, creating a structural tailwind for NOI growth that is underappreciated by the market. Furthermore, AHR’s balance sheet strength—net debt to EBITDA improved to 3.0x from 3.4x year-end 2025—and access to dry powder via $527.4 million in unsettled ATM forward sales and an $800 million unsecured revolver with no outstanding borrowings provide ample liquidity to execute its pipeline without dilutive equity issuance or increased leverage, positioning the company to capitalize on accretive deployment through 2026 and beyond.
AHR’s Trilogy (ISHC) segment is experiencing a sustained inflection point in profitability, with same-store NOI margins exceeding 20% for the first time since COVID—a milestone achieved through deliberate payor quality mix improvement, where 75.5% of resident days now reflect higher-acuity, Medicare Advantage-aligned residents (up 60 basis points quarter-over-quarter and 200 basis points on a total portfolio basis), directly supporting premium pricing power. This shift is amplified by Trilogy’s proprietary dynamic revenue software, which enables daily unit pricing based on real-time demand and unit attributes, creating a significant tailwind for revenue optimization that competitors lack. Management noted that Trilogy’s skilled nursing rate is growing at 5% annually—well ahead of inflation—due to a substantial private-pay component and selective Medicare Advantage partnerships yielding 6.6% rate growth last quarter, demonstrating the company’s ability to decouple reimbursement from stagnant Medicare fee schedules. The segment also benefited from 14.5% same-store NOI growth and 91.2% occupancy (up 220 basis points), with margin expansion driven by both occupancy leverage and a strategic shift toward higher-margin independent living and assisted living assets in the development pipeline. As Trilogy pursues regional scale in Wisconsin—targeting five to six campuses to unlock synergies from shared employees and regional directors—AHR’s platform approach, anchored by Trilogy as an operating partner, allows for immediate occupancy ramp and rate optimization post-acquisition, accelerating non-same-store NOI growth. This operational excellence, combined with the demographic tailwind of the aging 80+ population and near-historic-low new supply in senior housing, positions Trilogy as a compounding growth engine that the market is underestimating, particularly as AHR continues to divest low-growth outpatient medical and triple-net assets (now under 6% of the portfolio) to redeploy capital into these higher-return opportunities.

American Healthcare REIT (AHR) is positioned to capture significant value from its strategic focus on high-growth SHOP assets, which delivered 19.7% same-store NOI growth in Q1 2026 and expanded NOI margins by 215 basis points to 20.6%, driven by superior operator execution and dynamic revenue management. The company has successfully executed on its acquisition strategy, closing $249.2 million in SHOP deals year-to-date, including $162.8 million in Q1 and $86.4 million post-quarter in Georgia and South Carolina, with a robust pipeline of over $650 million in awarded deals—80% involving existing operators where AHR holds informational advantages through deep relationships and operator-first underwriting. This enables AHR to acquire assets below replacement cost in supply-constrained markets, leveraging certificate-of-need (CON) regimes as a durable competitive moat that limits new skilled nursing supply, particularly in key states like Wisconsin where Trilogy is pursuing regional scale. The development pipeline, totaling $173.9 million in-process with $52.4 million funded, is heavily weighted toward Trilogy campus expansions and independent living villas—asset types with higher margins—and extends AHR’s earnings runway through integrated senior health campuses that benefit from operational synergies across independent living, assisted living, and skilled nursing under one roof. Management’s statement that “We are still buying below replacement cost” underscores a persistent valuation advantage, especially as construction costs rise and new supply remains constrained by CON laws and unfavorable development economics, creating a structural tailwind for NOI growth that is underappreciated by the market. Furthermore, AHR’s balance sheet strength—net debt to EBITDA improved to 3.0x from 3.4x year-end 2025—and access to dry powder via $527.4 million in unsettled ATM forward sales and an $800 million unsecured revolver with no outstanding borrowings provide ample liquidity to execute its pipeline without dilutive equity issuance or increased leverage, positioning the company to capitalize on accretive deployment through 2026 and beyond.
AHR’s Trilogy (ISHC) segment is experiencing a sustained inflection point in profitability, with same-store NOI margins exceeding 20% for the first time since COVID—a milestone achieved through deliberate payor quality mix improvement, where 75.5% of resident days now reflect higher-acuity, Medicare Advantage-aligned residents (up 60 basis points quarter-over-quarter and 200 basis points on a total portfolio basis), directly supporting premium pricing power. This shift is amplified by Trilogy’s proprietary dynamic revenue software, which enables daily unit pricing based on real-time demand and unit attributes, creating a significant tailwind for revenue optimization that competitors lack. Management noted that Trilogy’s skilled nursing rate is growing at 5% annually—well ahead of inflation—due to a substantial private-pay component and selective Medicare Advantage partnerships yielding 6.6% rate growth last quarter, demonstrating the company’s ability to decouple reimbursement from stagnant Medicare fee schedules. The segment also benefited from 14.5% same-store NOI growth and 91.2% occupancy (up 220 basis points), with margin expansion driven by both occupancy leverage and a strategic shift toward higher-margin independent living and assisted living assets in the development pipeline. As Trilogy pursues regional scale in Wisconsin—targeting five to six campuses to unlock synergies from shared employees and regional directors—AHR’s platform approach, anchored by Trilogy as an operating partner, allows for immediate occupancy ramp and rate optimization post-acquisition, accelerating non-same-store NOI growth. This operational excellence, combined with the demographic tailwind of the aging 80+ population and near-historic-low new supply in senior housing, positions Trilogy as a compounding growth engine that the market is underestimating, particularly as AHR continues to divest low-growth outpatient medical and triple-net assets (now under 6% of the portfolio) to redeploy capital into these higher-return opportunities.

▼ Bear case

American Healthcare REIT (AHR) faces mounting pressure from decelerating Medicare reimbursement trends, which management acknowledged as a headwind requiring proactive expense management at Trilogy to offset stagnant government-paid rates, with Gabriel Willhite explicitly stating that “the Medicare growth rate is decelerating a little bit” and is “triggered off inflation, and as inflation comes down, that number comes down as well.” This dynamic threatens to compress margins in the skilled nursing component of Trilogy’s portfolio, where Medicaid dependence remains high (60–70% in typical SNFs), and despite AHR’s advantaged payer mix, the company’s ability to sustain 5% annual skilled nursing rate growth—cited as ahead of inflation—relies heavily on private-pay volumes and selective Medicare Advantage partnerships that may not be scalable or durable if broader economic pressures reduce private-pay demand or if MA plans shift toward lower-cost providers. Furthermore, the company’s reliance on dynamic revenue software and operator-specific strategies introduces execution risk; while Trilogy’s pricing technology is cited as a “significant tailwind,” the real-world efficacy of daily unit price adjustments at scale remains unproven in a broadening competitive landscape, and any slowdown in occupancy growth—currently at 91.2% for Trilogy and 88.6% for SHOP—could quickly reverse margin expansion gains, especially as the benefits of occupancy leverage diminish near stabilization levels. The market may be overestimating the sustainability of double-digit same-store NOI growth, particularly given that Q1 SHOP performance showed only a 9.3% sequential increase from Q4 2025, prompting Brian Peay to express pause despite long-term conviction, suggesting near-term momentum is fading and the 15–19% full-year SHOP guidance may be overly optimistic without continued inflection in occupancy or pricing power.
AHR’s external growth strategy, while supported by a $650 million pipeline and recent equity raises, carries significant execution and valuation risks that the market is overlooking, particularly the company’s assertion that it is “still buying below replacement cost” in an environment where construction costs continue to rise and cap rates have compressed 25–50 basis points over the last year, making true value-accretive deals increasingly scarce. Stefan Oh acknowledged that underwriting yields have not changed meaningfully despite more players entering the space, implying that AHR may be paying elevated prices to win bids in a competitive market, which could erode future NOI growth and returns on invested capital. The company’s heavy reliance on off-market deals (about half of the pipeline) and existing operators (80% of pipeline) creates concentration risk, as any deterioration in operator performance—or loss of exclusivity in those relationships—could jeopardize pipeline execution. Additionally, the ATM forward sale program, while providing liquidity, introduces potential overhang; the recent pricing of a 14 million-share offering ($705.6 million gross proceeds) adds to an already substantial unsettled forward position ($527.4 million), and if the stock fails to appreciate as expected, the forward sales could result in dilutive settlement at lower prices, undermining the perceived benefit of non-dilutive capital raises. Finally, AHR’s disposition of outpatient medical assets—while framed as a shift to higher-growth SHOP—may be premature, as the segment benefits from similar demographic tailwinds (aging population, lack of new supply) and pandemic-resilient occupancy, and selling a third of these holdings at current prices could leave the company overexposed to cyclical SHOP performance if senior housing demand softens, especially given that triple-net and outpatient medical now comprise less than 6% of the portfolio and are described as “shrinking every day,” reducing diversification benefits just as market volatility in senior living increases.

American Healthcare REIT (AHR) faces mounting pressure from decelerating Medicare reimbursement trends, which management acknowledged as a headwind requiring proactive expense management at Trilogy to offset stagnant government-paid rates, with Gabriel Willhite explicitly stating that “the Medicare growth rate is decelerating a little bit” and is “triggered off inflation, and as inflation comes down, that number comes down as well.” This dynamic threatens to compress margins in the skilled nursing component of Trilogy’s portfolio, where Medicaid dependence remains high (60–70% in typical SNFs), and despite AHR’s advantaged payer mix, the company’s ability to sustain 5% annual skilled nursing rate growth—cited as ahead of inflation—relies heavily on private-pay volumes and selective Medicare Advantage partnerships that may not be scalable or durable if broader economic pressures reduce private-pay demand or if MA plans shift toward lower-cost providers. Furthermore, the company’s reliance on dynamic revenue software and operator-specific strategies introduces execution risk; while Trilogy’s pricing technology is cited as a “significant tailwind,” the real-world efficacy of daily unit price adjustments at scale remains unproven in a broadening competitive landscape, and any slowdown in occupancy growth—currently at 91.2% for Trilogy and 88.6% for SHOP—could quickly reverse margin expansion gains, especially as the benefits of occupancy leverage diminish near stabilization levels. The market may be overestimating the sustainability of double-digit same-store NOI growth, particularly given that Q1 SHOP performance showed only a 9.3% sequential increase from Q4 2025, prompting Brian Peay to express pause despite long-term conviction, suggesting near-term momentum is fading and the 15–19% full-year SHOP guidance may be overly optimistic without continued inflection in occupancy or pricing power.
AHR’s external growth strategy, while supported by a $650 million pipeline and recent equity raises, carries significant execution and valuation risks that the market is overlooking, particularly the company’s assertion that it is “still buying below replacement cost” in an environment where construction costs continue to rise and cap rates have compressed 25–50 basis points over the last year, making true value-accretive deals increasingly scarce. Stefan Oh acknowledged that underwriting yields have not changed meaningfully despite more players entering the space, implying that AHR may be paying elevated prices to win bids in a competitive market, which could erode future NOI growth and returns on invested capital. The company’s heavy reliance on off-market deals (about half of the pipeline) and existing operators (80% of pipeline) creates concentration risk, as any deterioration in operator performance—or loss of exclusivity in those relationships—could jeopardize pipeline execution. Additionally, the ATM forward sale program, while providing liquidity, introduces potential overhang; the recent pricing of a 14 million-share offering ($705.6 million gross proceeds) adds to an already substantial unsettled forward position ($527.4 million), and if the stock fails to appreciate as expected, the forward sales could result in dilutive settlement at lower prices, undermining the perceived benefit of non-dilutive capital raises. Finally, AHR’s disposition of outpatient medical assets—while framed as a shift to higher-growth SHOP—may be premature, as the segment benefits from similar demographic tailwinds (aging population, lack of new supply) and pandemic-resilient occupancy, and selling a third of these holdings at current prices could leave the company overexposed to cyclical SHOP performance if senior housing demand softens, especially given that triple-net and outpatient medical now comprise less than 6% of the portfolio and are described as “shrinking every day,” reducing diversification benefits just as market volatility in senior living increases.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the REIT - Healthcare Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WELL	Welltower Inc.	172.91 Bn	122.84	12.78	17.93 Bn
2	VTR	Ventas, Inc.	46.62 Bn	179.03	7.60	-
3	DOC	Healthpeak Properties, Inc.	15.34 Bn	69.22	-33.80	0.25 Bn
4	OHI	Omega Healthcare Investors Inc	15.14 Bn	23.22	12.25	0.43 Bn
5	AHR	American Healthcare REIT, Inc.	10.71 Bn	194.58	4.76	1.51 Bn
6	CTRE	CareTrust REIT, Inc.	9.45 Bn	28.24	199.40	0.50 Bn
7	HR	Healthcare Realty Trust Inc	7.33 Bn	-	5.04	4.10 Bn
8	SBRA	Sabra Health Care REIT, Inc.	5.09 Bn	36.93	17.13	0.04 Bn

Research Tools

Developers

About

Investment Thesis

Customer Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Customer Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password